For the quarter ending 2026-03-31, BBLG has $4,979,305 in assets. $309,386 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 4,530,040 | 5,334,322 | 6,049,084 | 6,640,468 |
| Advances on research and development contract services | 208,972 | 208,972 | 220,286 | 208,972 |
| Prepaid insurance | 170,527 | 232,946 | 71,429 | 142,776 |
| Prepaid financing costs | 51,957 | - | - | - |
| Interest receivable | 7,809 | 9,895 | - | - |
| Prepaid expenses | 10,000 | 10,000 | 10,000 | 10,000 |
| Total current assets | 4,979,305 | 5,796,135 | 6,350,799 | 7,002,216 |
| Total assets | 4,979,305 | 5,796,135 | 6,350,799 | 7,002,216 |
| Accounts payable and accrued expenses | 308,948 | 417,884 | 333,081 | 403,729 |
| Warrant liability | 438 | 703 | 1,201 | 2,413 |
| Total current liabilities | 309,386 | 418,587 | 334,282 | 406,142 |
| Total liabilities | 309,386 | 418,587 | 334,282 | 406,142 |
| Common stock, 0.001 par value per share 100,000,000 shares authorized 1,795,260 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 1,795 | 1,795 | 1,795 | 1,685 |
| Additional paid-in capital | 93,564,481 | 93,506,122 | 93,460,448 | 93,373,378 |
| Accumulated deficit | -88,896,357 | -88,130,369 | -87,445,726 | -86,778,989 |
| Total stockholders equity | 4,669,919 | 5,377,548 | 6,016,517 | 6,596,074 |
| Total liabilities and stockholders equity | 4,979,305 | 5,796,135 | 6,350,799 | 7,002,216 |
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)